The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Isatuximab combination therapy approved by the European Commission
On June 2, 2020, the combination of isatuximab (isa) with pomalidomide and dexamethasone (pom-dex) received approval from the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM).1
This decision was based on promising data from the phase III ICARIA-MM study (NCT02990338), which uncovered a significantly improved progression-free survival rate in patients receiving isa in combination with pom-dex vs pom-dex alone. In adult patients with RRMM, the triplet combination regimen significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone. Read the MM Hub coverage of the ICARIA-MM trial here.
For further information on the indications of isa + pom-dex in this setting, read the European Medicines Agency’s Committee for Medicinal Products for Human Use positive opinion article on the MM Hub here.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content